1814. Aberrant Epigenetic Modifications of LPHN2 Function as a Potential Cisplatin-Specific Biomarker for Human Gastrointestinal Cancer.
Jeon MS, Song SH, Yun J, Kang JY, Kim HP, Han SW, Kim TY.
Cancer Res Treat. 2016 Apr;48(2):676-86. doi: 10.4143/crt.2015.153. Epub 2015 Sep 22.Link
1813. Reduced cohesin destabilizes high-level gene amplification by disrupting pre-replication complex bindings in human cancers with chromosomal instability.
Yun J, Song SH, Kang JY, Park J, Kim HP, Han SW, Kim TY.
1812. Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors.
YaYang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, Min B, Her JH, Cho SY, Keam B, Lee SH, Kim DW, Hwang YK, Heo DS.
Cancer Immunol Res. 2016 Mar;4(3):215-24. doi: 10.1158/2326-6066.CIR-15-0118. Epub 2016 Jan 19.Link
Int J Immunopathol Pharmacol. 2016 Dec;29(4):812-817. Epub 2016 Oct 19.Link
1810. In vivo monitoring of transfected DNA, gene expression kinetics, and cellular immune responses in mice immunized with a human NIS gene-expressing plasmid.
Son HY, Jeon YH, Chung JK, Kim CW.
Int J Immunopathol Pharmacol. 2016 Dec;29(4):612-625. Epub 2016 Sep 9.Link
1809. ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
Baik SH, Lee J, Lee YS, Jang JY, Kim CW.
Exp Mol Med. 2016 Mar 25;48:e222. doi: 10.1038/emm.2015.126.Link
1808. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
Mol Cancer Ther. 2016 Jun;15(6):1387-96. doi: 10.1158/1535-7163.MCT-15-0089. Epub 2016 Feb 16.Link